Search

Your search keyword '"Schweizer, Michael T."' showing total 384 results
Start Over Author "Schweizer, Michael T."
384 results on '"Schweizer, Michael T."'

1. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates

Author

Ajkunic, Azra, Sayar, Erolcan, Roudier, Martine P., Patel, Radhika A., Coleman, Ilsa M., De Sarkar, Navonil, Hanratty, Brian, Adil, Mohamed, Zhao, Jimmy, Zaidi, Samir, True, Lawrence D., Sperger, Jamie M., Cheng, Heather H., Yu, Evan Y., Montgomery, Robert B., Hawley, Jessica E., Ha, Gavin, Persse, Thomas, Galipeau, Patricia, Lee, John K., Harmon, Stephanie A., Corey, Eva, Lang, Joshua M., Sawyers, Charles L., Morrissey, Colm, Schweizer, Michael T., Gulati, Roman, Nelson, Peter S., and Haffner, Michael C.

Published
2024
Full Text
View/download PDF

2. A Multicenter Evaluation of Treatment-associated Changes in Body Composition in Men With Germ Cell Tumors of the Testis: Implications for Adverse Events and Complications

Author

Buxton, Claire, Schmeusser, Benjamin N., Holt, Sarah K., Patil, Dattatraya, Phuong, Anthea, Chahine, Sophia, Marquardt, J. Peter, O’Malley, Ryan, Laidlaw, Grace, Schade, George R., Lin, Daniel W., Schweizer, Michael T., Yezefski, Todd, Yu, Evan Y., Montgomery, Bruce, Fintelmann, Florian J., Master, Viraj A., and Psutka, Sarah P.

Published
2024
Full Text
View/download PDF

3. DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes

Author

Graham, Laura S., Henderson, Nicholas C., Kellezi, Olesia, Hwang, Clara, Barata, Pedro C., Bilen, Mehmet A., Kilari, Deepak, Pierro, Michael, Thapa, Bicky, Tripathi, Abhishek, Mo, George, Labriola, Matthew, Park, Joseph J., Rothstein, Shoshana, Garje, Rohan, Koshkin, Vadim S., Patel, Vaibhav G., Dorff, Tanya, Armstrong, Andrew J., McKay, Rana R., Alva, Ajjai, and Schweizer, Michael T.

Published
2024
Full Text
View/download PDF

4. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

Author

Orme, Jacob J., Taza, Fadi, De Sarkar, Navonil, Tewari, Alok K., Arsalan Naqvi, Syed, Riaz, Irbaz B., Childs, Daniel S., Omar, Noha, Adra, Nabil, Ashkar, Ryan, Cheng, Heather H., Schweizer, Michael T., Sokolova, Alexandra O., Agarwal, Neeraj, Barata, Pedro, Sartor, Oliver, Bastos, Diogo, Smaletz, Oren, Berchuck, Jacob E., McClure, Heather, Taplin, Mary-Ellen, Aggarwal, Rahul, Sternberg, Cora N., Vlachostergios, Panagiotis J., Alva, Ajjai S., Mehra, Niven, Nelson, Peter S., Hwang, Justin, Dehm, Scott M., Shi, Qian, Fleischmann, Zoe, Sokol, Ethan S., Elliott, Andrew, Huang, Haojie, Bryce, Alan, Marshall, Catherine H., and Antonarakis, Emmanuel S.

Published
2024
Full Text
View/download PDF

5. Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study

Author

Raychaudhuri, Ruben, Mo, George, Tuchayi, Abuzar Moradi, Graham, Laura, Gulati, Roman, Pritchard, Colin C., Haffner, Michael C., Yezefski, Todd, Hawley, Jessica E., Cheng, Heather H., Yu, Evan Y., Grivas, Petros, Montgomery, Robert B., Nelson, Peter S., Chen, Delphine L., Hope, Thomas, Iravani, Amir, and Schweizer, Michael T.

Published
2024
Full Text
View/download PDF

6. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations

Author

Park, Joseph J., Chu, Alec, Li, Jinju, Ali, Alicia, McKay, Rana R., Hwang, Clara, Labriola, Matthew K., Jang, Albert, Kilari, Deepak, Mo, George, Ravindranathan, Deepak, Graham, Laura S., Sokolova, Alexandra, Tripathi, Abhishek, Pilling, Amanda, Jindal, Tanya, Ravindra, Aditya, Cackowski, Frank C., Sweeney, Patrick L., Thapa, Bicky, Amery, Taylor S., Heath, Elisabeth I., Garje, Rohan, Zakharia, Yousef, Koshkin, Vadim S., Bilen, Mehmet A., Schweizer, Michael T., Barata, Pedro C., Dorff, Tanya B., Cieslik, Marcin, Alva, Ajjai S., and Armstrong, Andrew J.

Published
2024
Full Text
View/download PDF

7. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer

Author

Schweizer, Michael T., Gulati, Roman, Yezefski, Todd, Cheng, Heather H., Mostaghel, Elahe, Haffner, Michael C., Patel, Radhika A., De Sarkar, Navonil, Ha, Gavin, Dumpit, Ruth, Woo, Brianna, Lin, Aaron, Panlasigui, Patrick, McDonald, Nerina, Lai, Michael, Nega, Katie, Hammond, Jeannette, Grivas, Petros, Hsieh, Andrew, Montgomery, Bruce, Nelson, Peter S., and Yu, Evan Y.

Published
2023
Full Text
View/download PDF

10. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Author

Aggarwal, Rahul R, Schweizer, Michael T, Nanus, David M, Pantuck, Allan J, Heath, Elisabeth I, Campeau, Eric, Attwell, Sarah, Norek, Karen, Snyder, Margo, Bauman, Lisa, Lakhotia, Sanjay, Feng, Felix Y, Small, Eric J, Abida, Wassim, and Alumkal, Joshi J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Urologic Diseases, Cancer, Clinical Research, Prostate Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Aged, Aged, 80 and over, Androstenes, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Disease-Free Survival, Drug Resistance, Neoplasm, Humans, Male, Middle Aged, Neoplasm Metastasis, Nitriles, Phenylthiohydantoin, Progression-Free Survival, Prostatic Neoplasms, Castration-Resistant, Receptors, Androgen, Treatment Outcome, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeZEN-3694 is a bromodomain extraterminal inhibitor (BETi) with activity in androgen-signaling inhibitor (ASI)-resistant models. The safety and efficacy of ZEN-3694 plus enzalutamide was evaluated in a phase Ib/IIa study in metastatic castration-resistant prostate cancer (mCRPC).Patients and methodsPatients had progressive mCRPC with prior resistance to abiraterone and/or enzalutamide. 3+3 dose escalation was followed by dose expansion in parallel cohorts (ZEN-3694 at 48 and 96 mg orally once daily, respectively).ResultsSeventy-five patients were enrolled (N = 26 and 14 in dose expansion at low- and high-dose ZEN-3694, respectively). Thirty (40.0%) patients were resistant to abiraterone, 34 (45.3%) to enzalutamide, and 11 (14.7%) to both. ZEN-3694 dosing ranged from 36 to 144 mg daily without reaching an MTD. Fourteen patients (18.7%) experienced grade ≥3 toxicities, including three patients with grade 3 thrombocytopenia (4%). An exposure-dependent decrease in whole-blood RNA expression of BETi targets was observed (up to fourfold mean difference at 4 hours post-ZEN-3694 dose; P ≤ 0.0001). The median radiographic progression-free survival (rPFS) was 9.0 months [95% confidence interval (CI), 4.6-12.9] and composite median radiographic or clinical progression-free survival (PFS) was 5.5 months (95% CI, 4.0-7.8). Median duration of treatment was 3.5 months (range, 0-34.7+). Lower androgen receptor (AR) transcriptional activity in baseline tumor biopsies was associated with longer rPFS (median rPFS 10.4 vs. 4.3 months).ConclusionsZEN-3694 plus enzalutamide demonstrated acceptable tolerability and potential efficacy in patients with ASI-resistant mCRPC. Further prospective study is warranted including in mCRPC harboring low AR transcriptional activity.

Published
2020

11. PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer

Author

Koshkin, Vadim S., Patel, Vaibhav G., Ali, Alicia, Bilen, Mehmet A., Ravindranathan, Deepak, Park, Joseph J., Kellezi, Olesia, Cieslik, Marcin, Shaya, Justin, Cabal, Angelo, Brown, Landon, Labriola, Matthew, Graham, Laura S., Pritchard, Colin, Tripathi, Abhishek, Nusrat, Sanober, Barata, Pedro, Jang, Albert, Chen, Shuang R., Garje, Rohan, Acharya, Luna, Hwang, Clara, Pilling, Amanda, Oh, William, Jun, Tomi, Natesan, Divya, Nguyen, Chris, Kilari, Deepak, Pierro, Michael, Thapa, Bicky, Cackowski, Frank, Mack, Alleda, Heath, Elisabeth, Marshall, Catherine H., Tagawa, Scott T., Halabi, Susan, Schweizer, Michael T., Armstrong, Andrew, Dorff, Tanya, Alva, Ajjai, and McKay, Rana

Published
2022
Full Text
View/download PDF

12. MP35-18 AGREEMENT BETWEEN TRANSURETHRAL RESECTION OF BLADDER TUMOR (TURBT) AND RADICAL CYSTECTOMY (RC) PATHOLOGY IN PATIENTS WITH BLADDER CANCER SUBTYPE HISTOLOGY

Author

Bakaloudi, Dimitra Rafailia, primary, Koehne, Elizabeth L., additional, Makrakis, Dimitrios, additional, Diamandopoulos, Leonidas N., additional, Grivas, Petros, additional, Winters, Brian R., additional, True, Lawrence D., additional, Tretiakova, Maria S., additional, Psutka, Sarah P., additional, Holt, Sarah K., additional, John, Gore L., additional, Lin, Daniel W., additional, Schade, George R., additional, Nyame, Yaw, additional, Hsieh, Andrew C., additional, Lee, John K., additional, Yezefski, Todd, additional, Hawley, Jessica, additional, Schweizer, Michael T., additional, Cheng, Heather H., additional, Yu, Evan Y., additional, Vakar-Lopez, Funda, additional, Montgomery, Bruce R., additional, and Wright, Jonathan, additional

Published
2024
Full Text
View/download PDF

14. Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program

Author

Diamantopoulos, Leonidas N., Holt, Sarah K., Khaki, Ali R., Sekar, Rishi R., Gadzinski, Adam, Nyame, Yaw A., Vakar-Lopez, Funda, Tretiakova, Maria S., Psutka, Sarah P., Gore, John L., Lin, Daniel W., Schade, George R., Hsieh, Andrew C., Lee, John K., Yezefski, Todd, Schweizer, Michael T., Cheng, Heather H., Yu, Evan Y., True, Lawrence D., Montgomery, Robert B., Grivas, Petros, and Wright, Jonathan L.

Published
2021
Full Text
View/download PDF

15. Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177 Lu-PSMA-617: A Retrospective Multicenter Cohort Study.

Author

Raychaudhuri, Ruben, Mo, George, Tuchayi, Abuzar Moradi, Graham, Laura, Gulati, Roman, Pritchard, Colin C., Haffner, Michael C., Yezefski, Todd, Hawley, Jessica E., Cheng, Heather H., Yu, Evan Y., Grivas, Petros, Montgomery, Robert B., Nelson, Peter S., Chen, Delphine L., Hope, Thomas, Iravani, Amir, and Schweizer, Michael T.

Subjects
DNA repair, PROSTATE-specific membrane antigen, CASTRATION-resistant prostate cancer, TUMOR suppressor genes, PROGRESSION-free survival, PROSTATE cancer
Abstract

PURPOSE: While 177Lu-PSMA-617 (LuPSMA) is an effective therapy for many patients with metastatic castration-resistant prostate cancer (mCRPC), biomarkers associated with outcomes are not well defined. We hypothesized that prostate cancer mutational profile may associate with clinical activity of LuPSMA. We devised a study to evaluate associations between mCRPC mutational profile with LuPSMA clinical outcomes. METHODS: This was a multicenter retrospective analysis of patients with mCRPC with next-generation sequencing (NGS) who received LuPSMA. PSA50 response (ie, ≥50% decline in prostate-specific antigen [PSA]) rate, PSA progression free survival (PSA PFS), and overall survival (OS) were compared between genetically defined subgroups. RESULTS: One hundred twenty-six patients with NGS results who received at least one cycle of LuPSMA were identified. The median age was 73 (IQR, 68-78) years, 124 (98.4%) received ≥1 prior androgen receptor-signaling inhibitor, and 121 (96%) received ≥1 taxane-based chemotherapy regimen. Fifty-eight (46%) patients with a DNA damage repair gene mutation (DNA damage response group) and 59 (46.8%) with a mutation in TP53 , RB1 , or PTEN tumor suppressor genes (TSG group) were identified. After adjusting for relevant confounders, the presence of ≥1 TSG mutation was associated with shorter PSA PFS (hazard ratio [HR], 1.93 [95% CI, 1.05 to 3.54]; P =.034) and OS (HR, 2.65 [95% CI, 1.15 to 6.11]; P =.023). There was improved OS favoring the DNA damage response group (HR, 0.37 [95% CI, 0.14 to 0.97]; P =.044) on multivariable analysis. Univariate analysis of patients with ATM mutations had significantly higher rates of PSA50 response, PSA PFS, and OS. CONCLUSION: Outcomes on LuPSMA varied on the basis of mutational profile. Prospective studies to define the clinical activity of LuPSMA in predefined genomic subgroups are justified. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

Author

Orme, Jacob J., primary, Taza, Fadi, additional, De Sarkar, Navonil, additional, Tewari, Alok K., additional, Arsalan Naqvi, Syed, additional, Riaz, Irbaz B., additional, Childs, Daniel S., additional, Omar, Noha, additional, Adra, Nabil, additional, Ashkar, Ryan, additional, Cheng, Heather H., additional, Schweizer, Michael T., additional, Sokolova, Alexandra O., additional, Agarwal, Neeraj, additional, Barata, Pedro, additional, Sartor, Oliver, additional, Bastos, Diogo, additional, Smaletz, Oren, additional, Berchuck, Jacob E., additional, McClure, Heather, additional, Taplin, Mary-Ellen, additional, Aggarwal, Rahul, additional, Sternberg, Cora N., additional, Vlachostergios, Panagiotis J., additional, Alva, Ajjai S., additional, Mehra, Niven, additional, Nelson, Peter S., additional, Hwang, Justin, additional, Dehm, Scott M., additional, Shi, Qian, additional, Fleischmann, Zoe, additional, Sokol, Ethan S., additional, Elliott, Andrew, additional, Huang, Haojie, additional, Bryce, Alan, additional, Marshall, Catherine H., additional, and Antonarakis, Emmanuel S., additional

Published
2023
Full Text
View/download PDF

18. Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy

Author

Sekar, Rishi R., Diamantopoulos, Leonidas N., Bakaloudi, Dimitra R., Khaki, Ali R., Grivas, Petros, Winters, Brian R., Vakar-Lopez, Funda, Tretiakova, Maria S., Psutka, Sarah P., Holt, Sarah K., Gore, John L., Lin, Daniel W., Schade, George R., Hsieh, Andrew C., Lee, John K., Yezefski, Todd, Schweizer, Michael T., Cheng, Heather H., Yu, Evan Y., True, Lawrence D., Montgomery, R. Bruce., and Wright, Jonathan L.

Published
2023
Full Text
View/download PDF

20. Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer

Author

Labrecque, Mark P., primary, Brown, Lisha G., additional, Coleman, Ilsa M., additional, Nguyen, Holly M., additional, Dalrymple, Susan, additional, Brennen, W. Nathaniel, additional, Isaacs, John T., additional, Li, Dapei, additional, Lakely, Bryce, additional, DeLucia, Diana C., additional, Lee, John K., additional, Schweizer, Michael T., additional, Lin, Daniel W., additional, Corey, Eva, additional, Nelson, Peter S., additional, and Morrissey, Colm, additional

Published
2023
Full Text
View/download PDF

21. Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer

Author

Hwang, Clara, primary, Henderson, Nicholas C., additional, Chu, Shih-Chun, additional, Holland, Brandon, additional, Cackowski, Frank C., additional, Pilling, Amanda, additional, Jang, Albert, additional, Rothstein, Shoshana, additional, Labriola, Matthew, additional, Park, Joseph J., additional, Ghose, Alyssa, additional, Bilen, Mehmet A., additional, Mustafa, Seema, additional, Kilari, Deepak, additional, Pierro, Michael J., additional, Thapa, Bicky, additional, Tripathi, Abhishek, additional, Garje, Rohan, additional, Ravindra, Aditya, additional, Koshkin, Vadim S., additional, Hernandez, Erik, additional, Schweizer, Michael T., additional, Armstrong, Andrew J., additional, McKay, Rana R., additional, Dorff, Tanya B., additional, Alva, Ajjai S., additional, and Barata, Pedro C., additional

Published
2023
Full Text
View/download PDF

22. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer

Author

Labrecque, Mark P., Coleman, Ilsa M., Brown, Lisha G., True, Lawrence D., Kollath, Lori, Lakely, Bryce, Nguyen, Holly M., Yang, Yu.C., da Costa, Rui M. Gil, Kaipainen, Arja, Coleman, Roger, Higano, Celestia S., Yu, Evan Y., Cheng, Heather H., Mostaghel, Elahe A., Montgomery, Bruce, Schweizer, Michael T., Hsieh, Andrew C., Lin, Daniel W., Corey, Eva, Nelson, Peter S., and Morrissey, Colm

Subjects
Thermo Fisher Scientific Inc., Bayer AG, Phenotypes -- Analysis -- Health aspects, Enzalutamide -- Analysis -- Health aspects, Abiraterone -- Analysis -- Health aspects, Genes -- Analysis -- Health aspects, Transcription (Genetics) -- Analysis -- Health aspects, Medical research -- Analysis -- Health aspects, Genomes -- Analysis -- Health aspects, Genomics -- Analysis -- Health aspects, RNA -- Analysis -- Health aspects, Scientific equipment industry -- Analysis -- Health aspects, Immunohistochemistry -- Analysis -- Health aspects, RNA sequencing -- Analysis -- Health aspects, Prostate cancer -- Genetic aspects -- Development and progression -- Analysis -- Health aspects, Pharmaceutical industry -- Analysis -- Health aspects, Cancer metastasis -- Genetic aspects -- Development and progression -- Analysis -- Health aspects, Biochemistry, Motor vehicle drivers, Clinical trials, Tumors, Gene expression, Health care industry, University of Washington
Abstract

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with diverse drivers of disease progression and mechanisms of therapeutic resistance. We conducted deep phenotypic characterization of CRPC metastases and patient-derived xenograft (PDX) lines using whole-genome RNA sequencing, gene set enrichment analysis, and immunohistochemistry. Our analyses revealed 5 mCRPC phenotypes based on the expression of well-characterized androgen receptor (AR) or neuroendocrine (NE) genes: AR-high tumors (ARPC), AR-low tumors (ARLPC), amphicrine tumors composed of cells coexpressing AR and NE genes (AMPC), double-negative tumors (i.e., [AR.sup.-]/[NE.sup.-]; DNPC), and tumors with small cell or NE gene expression without AR activity (SCNPC). RE1 silencing transcription factor (REST) activity, which suppresses NE gene expression, was lost in AMPC and SCNPC PDX models. However, knockdown of REST in cell lines revealed that attenuated REST activity drives the AMPC phenotype but is not sufficient for SCNPC conversion. We also identified a subtype of DNPC tumors with squamous differentiation and generated an encompassing 26-gene transcriptional signature that distinguished the 5 mCRPC phenotypes. Together, our data highlight the central role of AR and REST in classifying treatment-resistant mCRPC phenotypes. These molecular classifications could potentially guide future therapeutic studies and clinical trial design., Introduction The androgen receptor (AR) regulates cellular programs that promote the survival and proliferation of prostate cancer (PC) cells. Consequently, first-line treatment for metastatic PC centers on inhibiting AR activity [...]

Published
2019
Full Text
View/download PDF

23. Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage

Author

Chatterjee, Payel, Schweizer, Michael T., Lucas, Jared M., Coleman, Ilsa, Nyquist, Michael D., Frank, Sander B., Tharakan, Robin, Mostaghel, Elahe, Luo, Jun, Pritchard, Colin C., Lam, Hung- Ming, Corey, Eva, Antonarakis, Emmanuel S., Denmeade, Samuel R., and Nelson, Peter S.

Subjects
Cell Signaling Technologies -- Negotiation, mediation and arbitration, Cancer genetics, Monosaccharides -- Growth, DNA damage, Ionizing radiation, Genes, Biotechnology industries -- Negotiation, mediation and arbitration, DNA, Prostate cancer, Androgens, DNA repair, Protein kinases, Clinical trials, Tumors, Sex hormones, Company growth, Health care industry, Johns Hopkins University. School of Medicine -- Negotiation, mediation and arbitration
Abstract

Prostate cancer (PC) initially depends on androgen receptor (AR) signaling for survival and growth. Therapeutics designed to suppress AR activity serve as the primary intervention for advanced disease. However, supraphysiological androgen (SPA) concentrations can produce paradoxical responses leading to PC growth inhibition. We sought to discern the mechanisms by which SPA inhibits PC and to determine if molecular context associates with antitumor activity. SPA produced an AR-mediated, dose-dependent induction of DNA double-strand breaks, [G.sub.0]/[G.sub.1] cell-cycle arrest, and cellular senescence. SPA repressed genes involved in DNA repair and delayed the restoration of damaged DNA, which was augmented by poly (ADP-ribose) polymerase 1 inhibition. SPA-induced double- strand breaks were accentuated in BRCA2- deficient patients with PC, and combining SPA with poly (ADP-ribose) polymerase or DNA-dependent protein kinase inhibition further repressed growth. Next-generation sequencing was performed on biospecimens from patients with PC receiving SPA as part of ongoing phase II clinical trials. Patients with mutations in genes mediating homology-directed DNA repair were more likely to exhibit clinical responses to SPA. These results provide a mechanistic rationale for directing SPA therapy to patients with PC who have AR amplification or DNA repair deficiency and for combining SPA therapy with poly (ADP-ribose) polymerase inhibition., Introduction Androgens, the androgen receptor (AR), and the AR-signaling program are intimately associated with the pathogenesis of prostate cancer (PC) (1-3). Suppressing AR signaling through androgen-deprivation therapy (ADT) was determined [...]

Published
2019
Full Text
View/download PDF

28. Supplementary Figures from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes

Author

De Sarkar, Navonil, primary, Patton, Robert D., primary, Doebley, Anna-Lisa, primary, Hanratty, Brian, primary, Adil, Mohamed, primary, Kreitzman, Adam J., primary, Sarthy, Jay F., primary, Ko, Minjeong, primary, Brahma, Sandipan, primary, Meers, Michael P., primary, Janssens, Derek H., primary, Ang, Lisa S., primary, Coleman, Ilsa M., primary, Bose, Arnab, primary, Dumpit, Ruth F., primary, Lucas, Jared M., primary, Nunez, Talina A., primary, Nguyen, Holly M., primary, McClure, Heather M., primary, Pritchard, Colin C., primary, Schweizer, Michael T., primary, Morrissey, Colm, primary, Choudhury, Atish D., primary, Baca, Sylvan C., primary, Berchuck, Jacob E., primary, Freedman, Matthew L., primary, Ahmad, Kami, primary, Haffner, Michael C., primary, Montgomery, R. Bruce, primary, Corey, Eva, primary, Henikoff, Steven, primary, Nelson, Peter S., primary, and Ha, Gavin, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table S3 from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes

Author

De Sarkar, Navonil, primary, Patton, Robert D., primary, Doebley, Anna-Lisa, primary, Hanratty, Brian, primary, Adil, Mohamed, primary, Kreitzman, Adam J., primary, Sarthy, Jay F., primary, Ko, Minjeong, primary, Brahma, Sandipan, primary, Meers, Michael P., primary, Janssens, Derek H., primary, Ang, Lisa S., primary, Coleman, Ilsa M., primary, Bose, Arnab, primary, Dumpit, Ruth F., primary, Lucas, Jared M., primary, Nunez, Talina A., primary, Nguyen, Holly M., primary, McClure, Heather M., primary, Pritchard, Colin C., primary, Schweizer, Michael T., primary, Morrissey, Colm, primary, Choudhury, Atish D., primary, Baca, Sylvan C., primary, Berchuck, Jacob E., primary, Freedman, Matthew L., primary, Ahmad, Kami, primary, Haffner, Michael C., primary, Montgomery, R. Bruce, primary, Corey, Eva, primary, Henikoff, Steven, primary, Nelson, Peter S., primary, and Ha, Gavin, primary

Published
2023
Full Text
View/download PDF

30. Data from Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes

Author

De Sarkar, Navonil, primary, Patton, Robert D., primary, Doebley, Anna-Lisa, primary, Hanratty, Brian, primary, Adil, Mohamed, primary, Kreitzman, Adam J., primary, Sarthy, Jay F., primary, Ko, Minjeong, primary, Brahma, Sandipan, primary, Meers, Michael P., primary, Janssens, Derek H., primary, Ang, Lisa S., primary, Coleman, Ilsa M., primary, Bose, Arnab, primary, Dumpit, Ruth F., primary, Lucas, Jared M., primary, Nunez, Talina A., primary, Nguyen, Holly M., primary, McClure, Heather M., primary, Pritchard, Colin C., primary, Schweizer, Michael T., primary, Morrissey, Colm, primary, Choudhury, Atish D., primary, Baca, Sylvan C., primary, Berchuck, Jacob E., primary, Freedman, Matthew L., primary, Ahmad, Kami, primary, Haffner, Michael C., primary, Montgomery, R. Bruce, primary, Corey, Eva, primary, Henikoff, Steven, primary, Nelson, Peter S., primary, and Ha, Gavin, primary

Published
2023
Full Text
View/download PDF

31. MP50-14 A MULTICENTER EVALUATION OF THE PROGNOSTIC UTILITY OF CHANGES IN TREATMENT-ASSOCIATED BODY COMPOSITION IN MEN WITH GERM CELL TUMORS (GCT) OF THE TESTIS: IMPLICATIONS FOR ADVERSE EVENTS AND COMPLICATIONS

Author

Buxton, Claire, primary, Schmeusser, Benjamin N., additional, Holt, Sarah K., additional, Patil, Datta, additional, Phuong, Anthea, additional, Marquardt, J. Peter, additional, O'malley, Ryan, additional, Laidlaw, Grace, additional, Schade, George R., additional, Lin, Daniel W., additional, Schweizer, Michael T., additional, Yezefski, Todd, additional, Yu, Evan Y., additional, Montgomery, Bruce, additional, Fintelmann, Florian J., additional, Chahine, Sophia, additional, Master, Viraj A., additional, and Psutka, Sarah P., additional

Published
2023
Full Text
View/download PDF

33. Data from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Author

Aggarwal, Rahul R., primary, Schweizer, Michael T., primary, Nanus, David M., primary, Pantuck, Allan J., primary, Heath, Elisabeth I., primary, Campeau, Eric, primary, Attwell, Sarah, primary, Norek, Karen, primary, Snyder, Margo, primary, Bauman, Lisa, primary, Lakhotia, Sanjay, primary, Feng, Felix Y., primary, Small, Eric J., primary, Abida, Wassim, primary, and Alumkal, Joshi J., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Data from Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer

Author

DeLucia, Diana C., primary, Cardillo, Thomas M., primary, Ang, Lisa, primary, Labrecque, Mark P., primary, Zhang, Ailin, primary, Hopkins, James E., primary, De Sarkar, Navonil, primary, Coleman, Ilsa, primary, da Costa, Rui M. Gil, primary, Corey, Eva, primary, True, Lawrence D., primary, Haffner, Michael C., primary, Schweizer, Michael T., primary, Morrissey, Colm, primary, Nelson, Peter S., primary, and Lee, John K., primary

Published
2023
Full Text
View/download PDF

35. Supp Tables from MSH2 Loss in Primary Prostate Cancer

Author

Guedes, Liana B., primary, Antonarakis, Emmanuel S., primary, Schweizer, Michael T., primary, Mirkheshti, Nooshin, primary, Almutairi, Fawaz, primary, Park, Jong Chul, primary, Glavaris, Stephanie, primary, Hicks, Jessica, primary, Eisenberger, Mario A., primary, De Marzo, Angelo M., primary, Epstein, Jonathan I., primary, Isaacs, William B., primary, Eshleman, James R., primary, Pritchard, Colin C., primary, and Lotan, Tamara L., primary

Published
2023
Full Text
View/download PDF

36. Supp Fig S2 from MSH2 Loss in Primary Prostate Cancer

Author

Guedes, Liana B., primary, Antonarakis, Emmanuel S., primary, Schweizer, Michael T., primary, Mirkheshti, Nooshin, primary, Almutairi, Fawaz, primary, Park, Jong Chul, primary, Glavaris, Stephanie, primary, Hicks, Jessica, primary, Eisenberger, Mario A., primary, De Marzo, Angelo M., primary, Epstein, Jonathan I., primary, Isaacs, William B., primary, Eshleman, James R., primary, Pritchard, Colin C., primary, and Lotan, Tamara L., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Table 1 from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Author

Aggarwal, Rahul R., primary, Schweizer, Michael T., primary, Nanus, David M., primary, Pantuck, Allan J., primary, Heath, Elisabeth I., primary, Campeau, Eric, primary, Attwell, Sarah, primary, Norek, Karen, primary, Snyder, Margo, primary, Bauman, Lisa, primary, Lakhotia, Sanjay, primary, Feng, Felix Y., primary, Small, Eric J., primary, Abida, Wassim, primary, and Alumkal, Joshi J., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table 2 from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Author

Aggarwal, Rahul R., primary, Schweizer, Michael T., primary, Nanus, David M., primary, Pantuck, Allan J., primary, Heath, Elisabeth I., primary, Campeau, Eric, primary, Attwell, Sarah, primary, Norek, Karen, primary, Snyder, Margo, primary, Bauman, Lisa, primary, Lakhotia, Sanjay, primary, Feng, Felix Y., primary, Small, Eric J., primary, Abida, Wassim, primary, and Alumkal, Joshi J., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Tables 1-4 from Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer

Author

DeLucia, Diana C., primary, Cardillo, Thomas M., primary, Ang, Lisa, primary, Labrecque, Mark P., primary, Zhang, Ailin, primary, Hopkins, James E., primary, De Sarkar, Navonil, primary, Coleman, Ilsa, primary, da Costa, Rui M. Gil, primary, Corey, Eva, primary, True, Lawrence D., primary, Haffner, Michael C., primary, Schweizer, Michael T., primary, Morrissey, Colm, primary, Nelson, Peter S., primary, and Lee, John K., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 1 from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Author

Aggarwal, Rahul R., primary, Schweizer, Michael T., primary, Nanus, David M., primary, Pantuck, Allan J., primary, Heath, Elisabeth I., primary, Campeau, Eric, primary, Attwell, Sarah, primary, Norek, Karen, primary, Snyder, Margo, primary, Bauman, Lisa, primary, Lakhotia, Sanjay, primary, Feng, Felix Y., primary, Small, Eric J., primary, Abida, Wassim, primary, and Alumkal, Joshi J., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 2 from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Author

Aggarwal, Rahul R., primary, Schweizer, Michael T., primary, Nanus, David M., primary, Pantuck, Allan J., primary, Heath, Elisabeth I., primary, Campeau, Eric, primary, Attwell, Sarah, primary, Norek, Karen, primary, Snyder, Margo, primary, Bauman, Lisa, primary, Lakhotia, Sanjay, primary, Feng, Felix Y., primary, Small, Eric J., primary, Abida, Wassim, primary, and Alumkal, Joshi J., primary

Published
2023
Full Text
View/download PDF

46. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)

Author

Autio, Karen A, primary, Higano, Celestia S, additional, Nordquist, Luke, additional, Appleman, Leonard J, additional, Zhang, Tian, additional, Zhu, Xin-Hua, additional, Babiker, Hani, additional, Vogelzang, Nicholas J, additional, Prasad, Sandip M, additional, Schweizer, Michael T, additional, Madan, Ravi A, additional, Billotte, Stephane, additional, Cavazos, Nora, additional, Bogg, Orlaith, additional, Li, Ray, additional, Chan, Kam, additional, Cho, Helen, additional, Kaneda, Megan, additional, Wang, I-Ming, additional, Zheng, Jenny, additional, Tang, Szu-Yu, additional, Hollingsworth, Robert, additional, Kern, Kenneth A, additional, and Petrylak, Daniel P, additional

Published
2023
Full Text
View/download PDF

47. Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration

Author

Zengin, Zeynep B., Henderson, Nicholas C., Park, Joseph J., Ali, Alicia, Nguyen, Charles, Hwang, Clara, Barata, Pedro C., Bilen, Mehmet A., Graham, Laura, Mo, George, Kilari, Deepak, Tripathi, Abhishek, Labriola, Matthew, Rothstein, Shoshana, Garje, Rohan, Koshkin, Vadim S., Patel, Vaibhav G., Schweizer, Michael T., Armstrong, Andrew J., McKay, Rana R., Alva, Ajjai, and Dorff, Tanya

Abstract

Background: ARgene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance of these gene alterations in the context of ARTA treatment and clinical outcomes remains unclear. Methods: Patients with castration-resistant prostate cancer (CRPC) who had undergone genomic testing and received ARTA treatment were identified in the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) database. Patients were stratified according to the timing of genomic testing relative to the first ARTA treatment (pre-/post-ARTA). Clinical outcomes such as time to progression, PSA response, and overall survival were compared based on alteration types. Results: In total, 540 CRPC patients who received ARTA and had tissue-based (n= 321) and/or blood-based (n= 244) genomic sequencing were identified. Median age was 62 years (range 39−90) at the time of the diagnosis. Majority were White (72.2%) and had metastatic disease (92.6%) at the time of the first ARTA treatment. Pre-ARTA genomic testing was available in 24.8% of the patients, and ARmutations and amplifications were observed in 8.2% and 13.1% of the patients, respectively. Further, time to progression was longer in patients with ARamplifications (25.7 months) compared to those without an ARalteration (9.6 months; p= 0.03). In the post-ARTA group (n= 406), ARmutations and ARamplifications were observed in 18.5% and 35.7% of the patients, respectively. The most common mutation in post-ARTA group was L702H(9.9%). Conclusion: In this real-world clinicogenomics database-driven study we explored the development of ARalterations and their association with ARTA treatment outcomes. Our study showed that ARamplifications are associated with longer time to progression on first ARTA treatment. Further prospective studies are needed to optimize therapeutic strategies for patients with ARalterations.

Published
2024
Full Text
View/download PDF

48. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer

Author

Sayar, Erolcan, primary, Patel, Radhika A., additional, Coleman, Ilsa M., additional, Roudier, Martine P., additional, Zhang, Ailin, additional, Mustafi, Pallabi, additional, Low, Jin-Yih, additional, Hanratty, Brian, additional, Ang, Lisa S., additional, Bhatia, Vipul, additional, Adil, Mohamed, additional, Bakbak, Hasim, additional, Quigley, David A., additional, Schweizer, Michael T., additional, Hawley, Jessica E., additional, Kollath, Lori, additional, True, Lawrence D., additional, Feng, Felix Y., additional, Bander, Neil H., additional, Corey, Eva, additional, Lee, John K., additional, Morrissey, Colm, additional, Gulati, Roman, additional, Nelson, Peter S., additional, and Haffner, Michael C., additional

Published
2023
Full Text
View/download PDF

50. Reply by Authors

Author

Schweizer, Michael T., primary, True, Lawrence, additional, Gulati, Roman, additional, Zhao, Yibai, additional, Ellis, William, additional, Schade, George, additional, Montgomery, Bruce, additional, Goyal, Sonia, additional, Nega, Katie, additional, Hakansson, Alexander K., additional, Liu, Yang, additional, Davicioni, Elai, additional, Pienta, Kenneth, additional, Nelson, Peter S., additional, Lin, Daniel, additional, and Wright, Jonathan, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results